Video

Addressing Hyperkalemia Assessment

Todd Brothers, clinical assistant professor, University of Rhode Island, explains how to address hyperkalemia assessed in patients. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

Todd Brothers, clinical assistant professor, University of Rhode Island, explains how to address hyperkalemia assessed in patients. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Clinical Meeting & Exhibition in Las Vegas, Nevada.

Todd Brothers: In the acute care setting, the first and foremost—most patients are asymptomatic. So it’s not necessarily just the serum potassium level, but more importantly if they’re having EKG changes, or hemodynamic instability. If those 2 are identified then aggressive treatment, particularly with calcium gluconate to stabilize the cardiac membrane to prevent life-threatening arrhythmia, is paramount. If you assess that the patient doesn’t have a life-threatening event, you have a little bit more time on your hands, then you could go through different treatment options for the long-term or chronic type therapy.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Cavan - stock.adobe.com
Image Credit: © utah51 - stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com